Dec 23 (Reuters) - The U.S. Food and Drug Administration (FDA) has approved Acer Therapeutics Inc's drug for treating patients with a type of genetic disorder called urea cycle disorders, according to the health regulator's website. (Reporting by Raghav Mahobe in Bengaluru; Editing by Anil D'Silva)
Acer Therapeutics Inc.
Equities
ACER
US00444P1084
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |